<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419068</url>
  </required_header>
  <id_info>
    <org_study_id>2005−003562−42</org_study_id>
    <secondary_id>EudraCT no: 2005−003562−42</secondary_id>
    <secondary_id>REC ref: 06/Q0605/83</secondary_id>
    <nct_id>NCT00419068</nct_id>
  </id_info>
  <brief_title>Trial of Adjunctive Vitamin D in Tuberculosis Treatment</brief_title>
  <official_title>Trial of Adjunctive Vitamin D in Tuberculosis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Lung Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barts &amp; The London NHS Trust</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether vitamin D enhances response to standard
      antibiotic treatment for pulmonary tuberculosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to sputum culture conversion</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of bacillary kill</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-month culture conversion rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sputum smear conversion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Migliol Placebo Oil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected smear positive pulmonary tuberculosis.

          -  Age 18 years or older.

          -  Written informed consent to participate.

        Exclusion Criteria:

          -  Known intolerance of vitamin D or first-line anti-tuberculous therapy.

          -  Taking antituberculous therapy for more than six days in the six months preceding
             enrolment.

          -  Taking the following medication in the month preceding enrolment: oral corticosteroid
             therapy, immunosuppressant therapy or cytotoxic therapy.

          -  Taking the following medication at enrolment: benzothiadiazine derivatives, cardiac
             glycosides or antituberculous therapy other than rifampicin, isoniazid, pyrazinamide
             and ethambutol.

          -  Diagnosis of any of the following: sarcoidosis, hyperparathyroidism, nephrolithiasis,
             pulmonary silicosis, HIV infection, liver failure, renal failure or malignancy

          -  Infection with rifampicin-resistant organism (as demonstrated by rapid molecular
             testing)

          -  Biochemical disturbance at enrolment: serum corrected calcium &gt;2.66 mmol/l, serum AST
             &gt;120 IU/l, total serum bilirubin &gt; 40 micromol/l or serum creatinine &gt; 250 micromol/l

          -  Breastfeeding or pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian R Martineau, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher J Griffiths, FRCP FRCGP D Phil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Whipps Cross University Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newham University Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E13 8SL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2007</study_first_posted>
  <last_update_submitted>September 29, 2009</last_update_submitted>
  <last_update_submitted_qc>September 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

